STRATA Skin Sciences

STRATA Skin Sciences, Inc. is a medical technology company in Dermatology and Plastic Surgery. It engages in developing, commercializing and marketing products for the treatment of dermatologic conditions. The firm operates through the following segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The company was founded by Dina Gutkowicz-Krusin in December 1989 and is headquartered in Horsham, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

STRATA Skin Sciences pursues growth through international expansion and profitability

STRATA Skin Sciences is strategically focusing on increasing revenue per device and expanding internationally to drive growth.
While facing challenges in domestic billings and lower revenue, the company's cost-cutting measures are enhancing profitability.
The company's efforts to optimize operations and drive revenue growth position it well for future success.

STRATA Skin Sciences reports revenue growth and operational improvements in Q2 2024

STRATA Skin Sciences (SSKN) delivered a mixed performance in Q2 2024 with revenue growth, improved operational efficiency, and strategic financing.
The company showcased strengths in equipment revenue growth, expanding customer base, and effective cost management strategies.
Challenges remain in achieving profitability, sustaining growth momentum, and managing operational costs effectively.
Opportunities lie in leveraging marketing efforts, expanding product offerings, exploring new markets, and optimizing operational efficiency for future growth.

STRATA Skin Sciences reports solid Q3 performance with growth opportunities

STRATA Skin Sciences demonstrated solid financial performance in Q3 2024, leveraging improved revenue per XTRAC and cost management.
While facing challenges in device adoption and operating expenses, the company's DTC initiatives and cash position present growth opportunities.
By focusing on enhancing device utilization and investing in innovation, STRATA Skin Sciences can drive future revenue growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HORSHAM, Pa., Dec. 05, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that President and Chief Executive Officer Dr. Dolev Rafaeli will participate in the Benchmark Company 13th Annual Discovery Investor Conference that is being held on Wednesday, December 11, 2024, at the New York Athletic Club in New York City.

STRATA Skin Sciences to Participate in the Benchmark Company 13th Annual Discovery Investor Conference

STRATA Skin Sciences, Inc. (SSKN) Q3 2024 Earnings Call Transcript

HORSHAM, Pa., Nov. 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended September 30, 2024 and provides a corporate update.

STRATA Skin Sciences Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

HORSHAM, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that the United States District Court for the Eastern District of Pennsylvania entered a court order in favor of the Company in its complaint against LaserOptek America Corp. (“LaserOptek”), Monarch Aesthetic Services, Inc. d/b/a Monarch Laser Services (“MLS”), and The Pinnacle Health Group (“Pinnacle”), collectively referred to as the “Defendants.”

STRATA Skin Sciences Announces Favorable Court Order in Complaint Against LaserOptek, Monarch Laser Services, and The Pinnacle Health Group

HORSHAM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2024 financial results on Wednesday, November 13, 2024 after the market close.

STRATA Skin Sciences to Report Third Quarter 2024 Financial Results on November 13, 2024 and Provide Corporate Update

HORSHAM, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that JMEC Co., Ltd., its longstanding Japanese strategic partner and distributor, sponsored a seminar with two lectures on XTRAC® excimer devices on Saturday, October 12, 2024, at the 75th Annual Meeting of the Chubu Branch of the Japanese Dermatological Association held in Nagoya, Japan. Professor Kazutoshi Harada of Tokyo Medical University chaired the seminar.

STRATA Skin Sciences' XTRAC® Excimer Laser was Focus of Two Lectures at Major Japanese Annual Dermatology Conference

HORSHAM, Pa., Oct. 08, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that President and CEO Dr. Dolev Rafaeli will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Maxim Director of Research and Senior Healthcare Analyst Anthony Vendetti. The conference is being held virtually on October 15 – 17, 2024.

STRATA Skin Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

HORSHAM, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that President and CEO Dr. Dolev Rafaeli will present a corporate overview at the iAccess Alpha - Buyside Best Ideas Fall Conference 2024. The conference is being held virtually from September 24 – 25, 2024.

STRATA Skin Sciences to Present at the iAccess Alpha - Buyside Best Ideas Fall Conference 2024

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Strata Skin Sciences (SSKN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Despite Fast-paced Momentum, Strata Skin Sciences (SSKN) Is Still a Bargain Stock

HORSHAM, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that President and CEO Dr. Dolev Rafaeli will participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth Conference on Thursday, September 12, 2024, at the Yale Club in Midtown Manhattan, New York City.

STRATA Skin Sciences to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth Conference

HORSHAM, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that President and CEO Dr. Dolev Rafaeli will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held from September 9 - 11, 2024 at the Lotte New York Palace Hotel.

STRATA Skin Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Joey Delahoussaye - Investor Relations Dolev Rafaeli - Chief Executive Officer Chris Lesovitz - Chief Financial Officer Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the STRATA Skin Sciences Inc. Second Quarter 2024 Financial Results and Corporate Update Conference Call.

STRATA Skin Sciences, Inc. (SSKN) Q2 2024 Earnings Call Transcript

HORSHAM, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended June 30, 2024 and provides a corporate update.

STRATA Skin Sciences Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

HORSHAM, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report second quarter 2024 financial results on Wednesday, August 14, 2024 after the market close.

STRATA Skin Sciences to Report Second Quarter 2024 Financial Results on August 14, 2024 and Provide Corporate Update

HORSHAM, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that Dr. Dolev Rafaeli, President and Chief Executive Officer, and Christopher Lesovitz, Chief Financial Officer, will participate in the 9th Annual Virtual Needham MedTech & Diagnostics 1x1 Conference being held on August 12 – 13, 2024.

STRATA Skin Sciences to Participate in the 9th Annual Virtual Needham MedTech & Diagnostics 1x1 Conference

Study published in the Journal of Clinical and Aesthetic Dermatology showed TheraClear®X Photopneumatic Acne therapy is a viable treatment option for patients with acne, especially for whom other acne treatments are ineffective or are poorly tolerated Study published in the Journal of Clinical and Aesthetic Dermatology showed TheraClear®X Photopneumatic Acne therapy is a viable treatment option for patients with acne, especially for whom other acne treatments are ineffective or are poorly tolerated

STRATA Skin Sciences' TheraClear®X Acne Therapy System Found to be Safe and Effective for Acne Lesions Across All Fitzpatrick Skin Types with Favorable Tolerability and Patient Satisfaction as Published in Peer Reviewed Journal

HORSHAM, Penn., June 04, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its participation in two dermatology conferences in the month of June.

STRATA Skin Sciences to Participate in June Dermatology Conferences

STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q1 2024 Results Conference Call May 2, 2024 4:30 PM ET Company Participants Dolev Rafaeli - Chief Executive Officer Chris Lesovitz - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the STRATA Skin Sciences Inc. First Quarter of 2024 Financial Results and Corporate Update Conference Call.

STRATA Skin Sciences, Inc. (SSKN) Q1 2024 Earnings Call Transcript

HORSHAM, Penn., May 15, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2024 and provides a corporate update.

STRATA Skin Sciences Reports First Quarter 2024 Financial Results and Provides a Corporate Update

HORSHAM, Pa., May 14, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its installed base of TheraClear®X devices surpassed 100 at the end of the first quarter of 2024.

STRATA Skin Sciences Surpasses 100 Domestic Installations of TheraClear®X Devices as of March 31, 2024

HORSHAM, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that Dr. Dolev Rafaeli, President and Chief Executive Officer, and Christopher Lesovitz, Chief Financial Officer, will participate in the Benchmark Healthcare House Call Virtual 1x1 Investor Conference being held on May 21 – 22, 2024.

STRATA Skin Sciences to Participate in the Benchmark Healthcare House Call Virtual 1x1 Investor Conference

HORSHAM, Penn., May 08, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report first quarter 2024 financial results on Wednesday, May 15, 2024 after the market close.

STRATA Skin Sciences to Report First Quarter 2024 Financial Results on May 15, 2024 and Provide Corporate Update

HORSHAM, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the placement of six XTRAC® devices with dermatology clinics in the first quarter of 2024 that are considered “comebacks.” Comebacks are excimer placements with dermatology clinics that were previously active in the Company's partner program, then terminated their relationship with the Company at some point in the past but have now decided to return to STRATA under the partner program. Among these comebacks are Henry Ford Health System in Detroit, Integrated Dermatology Group, and several practices from the Schweiger Dermatology Group.

STRATA Skin Sciences Announces XTRAC® Comeback Placements in the First Quarter of 2024

HORSHAM, Penn., April 26, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10 that will become effective at 11:59 p.m. Eastern Time on June 6, 2024. The Company's common stock will begin trading on Nasdaq on a split-adjusted basis when the market opens on June 7, 2024 under the existing symbol, SSKN, and under a new CUSIP number, 86272A 305. This reverse stock split is primarily intended to bring the Company into compliance with Nasdaq's minimum bid price requirement for continued listing.

STRATA Skin Sciences Announces 1-for-10 Reverse Stock Split

HORSHAM, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that Dr. Dolev Rafaeli, President and Chief Executive Officer, will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2024. The conference is being held on April 30 – May 2, 2024 at the Paris Hotel & Casino in Las Vegas.

News for STRATA Skin Sciences Stock (SSKN)